Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Bevacizumab Stories

2012-02-14 15:28:52

Scientists at Dana-Farber Cancer Institute have identified a subtype of ovarian cancer able to build its own blood vessels, suggesting that such tumors might be especially susceptible to "anti-angiogenic" drugs that block blood vessel formation. In a study published in the online journal PloS ONE, the investigators estimate that the subtype may account for a third of all serous ovarian cancers, a common cancer of the surface of the ovaries. The discovery of the subtype, made by analyzing...

2012-02-09 09:00:00

RIDGEWOOD, N.J., Feb. 9, 2012 /PRNewswire-USNewswire/ -- The Valley Hospital is now offering patients with newly diagnosed glioblastoma multiforme (GBM) (brain tumor) the opportunity to take part in a clinical trial that produces and uses a vaccine produced from patients' own tissue. The study is being conducted to learn if it can improve the outcome for patients in the fight against this aggressive and deadly form of brain cancer. The Phase Two trial, headed by principal...

2012-02-07 09:30:00

VANCOUVER, British Columbia , Feb. 7, 2012 /PRNewswire/ -- Del Mar Pharmaceuticals today announced that a pre-clinical abstract entitled, "VAL083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme," will be presented April 1, 2012 at the American Association for Cancer Research (AACR) Annual Meeting, which is being held March 31 thru April 4, 2012 in Chicago, USA....

2012-01-30 06:00:00

MELBOURNE, Australia, Jan. 30, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announced today the publication of data in the scientific journal, Investigative Ophthalmology & Visual Science (IOVS), showing that VEGF-C expression is markedly up-regulated in corneal graft rejection. Importantly the data also showed that VEGF-C blockade, through administration of Circadian's lead development candidate VGX-100, a human antibody against VEGF-C,...

2012-01-27 12:00:00

Drug helps keep cancer from progressing SILVER SPRING, Md., Jan. 27, 2012 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes in the kidney. Inlyta...

2012-01-25 16:27:00

MOUNTAIN VIEW, Calif., Jan. 25, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced results of a clinical study evaluating the use of IRIDEX' MicroPulse laser therapy. The study examined the tissue-sparing therapy's effectiveness with patients diagnosed with central serous chorioretinopathy (CSC).(1) The study concluded tissue-sparing subvisible MicroPulse laser is superior to anti-VEGF injections for CSC, also known as CSR, an eye disease, which results in blurred...

2012-01-25 12:38:01

Finding could explain limited success of anti-angiogenesis treatments in breast cancer Cancer treatments designed to block the growth of blood vessels were found to increase the number of cancer stem cells in breast tumors in mice, suggesting a possible explanation for why these drugs don't lead to longer survival, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center. The drugs Avastin and Sutent have been looked at as potential breast cancer...

2012-01-17 17:21:00

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from the Bayer HealthCare Phase 3 CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial of Bayer's investigational compound regorafenib (BAY 73-4506). The study met its primary endpoint, showing statistically significant improvement in overall survival (OS) by 29% (HR=0.77, p=0.0052, median OS: 6.4 months...

2012-01-17 17:01:00

WAYNE, N.J., Jan. 17, 2012 /PRNewswire/ -- Bayer HealthCare today announced latest data on its investigational compound regorafenib (BAY 73-4506) from the Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial. The study met its primary endpoint, showing statistically significant improvement in overall survival (OS) by 29% (HR=0.77, p=0.0052, median OS: 6.4 months vs. 5.0 months for the placebo group) in patients with metastatic...

2012-01-08 16:30:00

MELBOURNE, Australia, Jan. 8, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre. The Phase 1 study will examine the safety and tolerability of escalating doses of VGX-100 in patients with advanced solid tumours who have no other standard treatment options both as a monotherapy and also...